Human Tissue Authority

The regulator for human tissue and organs


While the Executive implements this Strategy by way of business plans, there are a number of mechanisms in place by which the Authority steers, scrutinises and reviews performance.

The Authority holds four board meetings per year, one of which is in public and combined with an annual conference. These meetings provide the opportunity to assess a range of management information and more detailed reports on progress against elements of the Strategy. They also allow the Authority to hold the Executive to account for the HTA’s performance.

The board meetings, supplemented by two strategic development events, also provide the main means by which we set the direction on issues of strategic importance that emerge over the course of the year.

The Authority is supported in its work by two standing committees: the Audit and Risk Assurance Committee and the Remuneration Committee. In addition, ad hoc groups are created where significant input is required from Authority Members on major development or change issues.

There are three further standing groups, which report back to the Authority – the Stakeholder Group; the Histopathology Working Group; and the Transplantation Advisory Group – each comprising stakeholders, Authority Members and Executive staff. These groups are used to seek stakeholder views and advise the HTA on the impact of its regulatory activity.

Last updated on: 31 May 2016